Valuation: Exelixis, Inc.

Market Cap 13.4B 11.48B 10.74B 9.83B 18.45B 1,282B 18.69B 127B 49.48B 644B 50.32B 49.22B 2,130B P/E 2026 *
16.7x
P/E 2027 * 14.2x
Enterprise Value 12.66B 10.84B 10.14B 9.29B 17.43B 1,211B 17.66B 120B 46.73B 608B 47.52B 46.49B 2,012B EV / Sales 2026 *
4.96x
EV / Sales 2027 * 4.1x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+0.73%
1 week+5.54%
Current month+1.98%
1 month-2.82%
3 months+7.84%
6 months+22.88%
Current year+23.39%
1 week 52.11
Extreme 52.11
54.68
1 month 49.97
Extreme 49.97
56.95
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 10.04
Extreme 10.04
57.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap.
8/10/26 Sell

Director

-9,812 0.0039%
5/27/26 Free

Director

8,367 0.0033%
2/26/26 Free

General Counsel

23,119 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+0.73%+5.54%+39.99%+148.64% 13.4B
-3.00%+2.27%+73.26%+113.08% 72.12B
+1.90%+23.53%+59.48%+94.94% 65.85B
+5.12%+25.22%+5.13%-5.23% 29.28B
+0.55%+1.64%-4.63%+469.35% 27.47B
-4.82%+5.16%+45.85%+8.83% 26.7B
+0.47%+6.12%+37.01%-16.17% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
-2.88%0.00%+11.22%+549.07% 16.4B
-0.41%+0.54%+308.39%+204.37% 12.3B
Average -0.05%+7.59%+82.71%+195.58% 30.18B
Weighted average by Cap. -0.18%+9.12%+67.21%+157.90%

Financials

2026 *2027 *
Net sales 2.55B 2.19B 2.05B 1.87B 3.51B 244B 3.56B 24.16B 9.42B 123B 9.58B 9.37B 406B 2.87B 2.46B 2.3B 2.11B 3.95B 275B 4B 27.18B 10.6B 138B 10.78B 10.54B 456B
Net income 821M 703M 658M 602M 1.13B 78.52B 1.14B 7.77B 3.03B 39.44B 3.08B 3.01B 130B 974M 835M 781M 715M 1.34B 93.22B 1.36B 9.23B 3.6B 46.83B 3.66B 3.58B 155B
Net Debt -744M -638M -597M -546M -1.03B -71.23B -1.04B -7.05B -2.75B -35.78B -2.8B -2.73B -118B -1.62B -1.39B -1.3B -1.19B -2.23B -155B -2.26B -15.37B -5.99B -77.99B -6.09B -5.96B -258B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-08-21 $54.08 +0.73% 1,949,764
26-08-20 $53.69 -1.29% 1,950,664
26-08-19 $54.39 +2.39% 2,503,640
26-08-18 $53.12 +1.53% 1,290,526
26-08-17 $52.32 +2.11% 2,372,576
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
54.08USD
Average target price
53.00USD
Spread / Average Target
-2.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock